These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 38613141

  • 1. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
    Friedman JS, Durham BH, Reiner AS, Yabe M, Petrova-Drus K, Dogan A, Pulitzer M, Busam KJ, Francis JH, Rampal RK, Ulaner GA, Reddy R, Yeh R, Hatzoglou V, Lacouture ME, Rotemberg V, Mazor RD, Hershkovitz-Rokah O, Shpilberg O, Goyal G, Go RS, Abeykoon JP, Rech K, Morlote D, Fidai S, Gannamani V, Zia M, Abdel-Wahab O, Panageas KS, Rosenblum MK, Diamond EL.
    Br J Haematol; 2024 Jul; 205(1):127-137. PubMed ID: 38613141
    [Abstract] [Full Text] [Related]

  • 2. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M, Cohen-Aubart F, Trefond L, Bauvois A, Amoura Z, Emile JF, Haroche J.
    Curr Oncol Rep; 2019 May 21; 21(7):62. PubMed ID: 31115724
    [Abstract] [Full Text] [Related]

  • 3. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ.
    Oncotarget; 2015 Aug 14; 6(23):19819-25. PubMed ID: 26110571
    [Abstract] [Full Text] [Related]

  • 4. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
    Geerlinks AV, Abla O.
    Paediatr Drugs; 2023 Jul 14; 25(4):399-409. PubMed ID: 37204611
    [Abstract] [Full Text] [Related]

  • 5. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.
    JAMA Oncol; 2018 Mar 01; 4(3):384-388. PubMed ID: 29188284
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mixed histiocytic disorders: Nature versus nurture?
    McClain K, Dimitrion P.
    Br J Haematol; 2024 Jul 01; 205(1):20-21. PubMed ID: 38763166
    [Abstract] [Full Text] [Related]

  • 10. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
    Bonometti A, Ferrario G, Parafioriti A, Giardino D, Simonetti F, Ginori A, Passoni E, Berti E, for AIRI, Associazione Italiana Ricerca Istiocitosi ONLUS.
    J Cutan Pathol; 2021 May 01; 48(5):637-643. PubMed ID: 33188581
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
    Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R.
    Mol Cancer Ther; 2019 Jun 01; 18(6):1149-1157. PubMed ID: 31015311
    [Abstract] [Full Text] [Related]

  • 13. Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes.
    Banks SA, Bhatti MT, Go RS, Abeykoon JP, Acosta-Medina AA, Hazim AZ, Goyal G, Young JR, Koster MJ, Vassallo R, Ryu JH, Davidge-Pitts CJ, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Garrity JA, Tobin WO, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group.
    Ophthalmology; 2023 Jan 01; 130(1):77-86. PubMed ID: 35932838
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. How I Diagnose Rosai-Dorfman Disease.
    Ravindran A, Rech KL.
    Am J Clin Pathol; 2023 Jul 05; 160(1):1-10. PubMed ID: 37167084
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE, Parsons DW.
    Hematology Am Soc Hematol Educ Program; 2015 Jul 05; 2015():559-64. PubMed ID: 26637772
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
    Aaroe A, Kurzrock R, Goyal G, Goodman AM, Patel H, Ruan G, Ulaner G, Young J, Li Z, Dustin D, Go RS, Diamond EL, Janku F.
    Blood Adv; 2023 Aug 08; 7(15):3984-3992. PubMed ID: 36857436
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
    Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O.
    Cancer Discov; 2015 Jan 08; 5(1):64-71. PubMed ID: 25324352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.